Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

Cheng Xue Qin(Monash University), Lucy V. Norling(Queen Mary University of London), Elizabeth A. Vecchio(Monash University), Eoin Brennan(University College Dublin), Lauren T. May(Monash University), Denise Wootten(Monash University), Catherine Godson(University College Dublin), Mauro Perretti(Queen Mary University of London), Rebecca H. Ritchie(Monash University)
British Journal of Pharmacology
July 7, 2022
Cited by 63Open Access
Full Text

Abstract

). Initially identified as a low-affinity 'relative' of FPR1, FPR2 presents complex and diverse biology. For instance, it is activated by several classes of agonists (from peptides to proteins and lipid mediators) and displays diverse expression patterns on myeloid cells as well as epithelial cells and endothelial cells, to name a few. Over the last decade, the pharmacology of FPR2 has progressed from being considered a weak chemotactic receptor to a master-regulator of the resolution of inflammation, the second phase of the acute inflammatory response. We propose that exploitation of the biology of FPR2 offers innovative ways to rectify chronic inflammatory states and represents a viable avenue to develop novel therapies. Recent elucidation of FPR2 structure will facilitate development of the anti-inflammatory and pro-resolving drugs of next decade.


Related Papers

No related papers found

Powered by citation graph analysis